Cuban Medicament for Diabetic Foot Extended to Venezuela
- Submitted by: admin
- South America
- Business and Economy
- Health and Medicine
- Science and Technology
- 04 / 08 / 2009
The specialist stressed that more than 50% of these patients were candidates to amputation, a procedure that was then only necessary in five cases.
Produced by CIGB scientists and specialists from the Angiology Institute, this biotechnological product (injectable) has been applied to more than 2,000 Cuban patients with ulcers resistant to all kind of conventional treatments.
Pérez highlighted that, in its three clinical trials, the medicine has shown its safety and efficiency for the healing of these ulcers in more than 80% of cases.
He also announced that, at present, the use of HEBERPROT-P is extended to the Primary Health Care system on the archipelago, for which a qualification course will be carried out in April (Diploma), with specialists from the entire country.
Likewise, the Cuba-Venezuela International Workshop will be held in Havana on April 9 and 10, in which Cuban voluntary workers offering their services in Comprehensive Diagnostic Centers of that South American nation will participate.
According to the World Health Organization, more than 170 million people on the planet suffer from Diabetes Mellitus, a figure that could double over the next few years, and adding that it will cause more deaths than AIDS.
Over 1,000 amputations caused by Diabetes are performed in Cuba annually, hence the importance of counting on this product, which is registered on the archipelago and also in Algeria, Argentina and Venezuela, and patented in the United States, Europe, China, Australia, Russia, South Africa, India, Mexico, Hong Kong and Singapore, among other nations, pointed out López.